Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 6, 1998, Pages 1365-1369

  Ioannides Demos, L L ^a   Liolios, L ^a   Wood, P ^a   Spicer, W J ^a   Mclean, A J ^b  

^a Rheumatology Unit   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TOBRAMYCIN;

AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0031805096     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.6.1365     Document Type: Article

References (13)

1. Bastone, E. B., S. C. Li, L. L. Ioannides-Demos, W. J. Spicer, and A. J. McLean. 1993. Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus or infusion dosing. Antimicrob. Agents Chemother. 37:914-917.
2. Begg, E. J., B. A. Peddie, S. T. Chambers, et al. 1992. Comparison of gentamicin dosing regimens using an in-vitro model. J. Antimicrob. Chemother. 29:427-433.
3. Ioannides-Demos, L. L., S. C. Li, E. B. Bastone, D. W. Spelman, R. Hooper, V. C. Cousins, and A. J. McLean. 1994. Absence of toxicity in patients with malignant otitis externa following long-term treatment with high dosage tobramycin. J. Antimicrob. Chemother. 34:267-274.
4. Li, S. C., L. L. Ioannides-Demos, W. J. Spicer, D. W. Spelman, N. Tong, and A. J. McLean. 1992. Prospective audit of the impact of an aminoglycoside pharmacokinetic and consultative service on the utilization patterns and clinical toxicology of aminoglycosides in a general hospital. Med. J. Aust. 157:308-311.
5. McLean, A. J., L. L. Ioannides-Demos, S. C. Li, E. B. Bastone, and W. J. Spicer. 1993. Bactericidal effect of gentamicin peak concentration provides a rationale for administration of bolus doses. J. Antimicrob. Chemother. 32: 301-305.
6. McLean, A. J., L. Liolios, E. B. Bastone, L. L. Ioannides-Demos, W. J. Spicer, and N. Christophidis. 1995. Concentration-dependence of gentamicin post-bolus peak effect on Escherichia coli kill kinetics. J. Antimicrob. Chemother. 35:444-446.
7. McLean, A. J., E. B. Bastone, L. L. Ioannides-Demos, and W. J. Spicer. 1994. Bactericidal effect of gentamicin trough concentration provides a rationale for administration of bolus doses and maintenance of trough levels. J. Antimicrob. Chemother. 33:999-1004.
8. McLean, A. J., L. L. Ioannides-Demos, W. J. Spicer, and N. Christophidis. 1996. Aminoglycoside dosing: one, two or three times a day? Med. J. Aust. 164:39-42.
9. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
10. Sawchuk, R. J., D. E. Zaske, R. J. Cipolle, et al. 1977. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin. Pharmacol. Ther. 21:362-365.
11. Sveska, K. J., B. D. Roff, D. K. Solomon, and R. P. Hoffman. 1985. Outcome of patients treated by an aminoglycoside pharmacokinetic dosing service. Am. J. Hosp. Pharm. 42:2472-2478.
12. Wood, P. J., L. L. Ioannides-Demos, E. B. Bastone, W. J. Spicer, and A. J. McLean. 1996. Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to tobramycin concentration-time profiles simulating in vivo holus or infusion dosing. Antimicrob. Agents Chemother. 40:1321-1324.
13. Wood, P. J., L. L. Ioannides-Demos, S. C. Li, T. Williams, B. Hickey, W. J. Spicer, R. E. Hooper, and A. J. McLean. 1996. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 51:369-373.